Swedbank Robur - Fund Management
Historical growth is no guarantee of future returns. Inflation has not been taken into account in the funds' returns. The value of the funds can both rise and fall, which is why there can be no guarantee that you will get back your original investment. Funds categorized as risk class 5-7 has a high risk both for increases and decreases in the value of the fund units. Fact Sheets (KIID), prospectuses and information about your rights are available on the website www.swedbankrobur.se

Swedbank Robur Healthcare C

Healthcare is an actively managed equity fund that mainly invests worldwide in large and medium-sized companies across a range of sectors in the healthcare industry, including pharmaceuticals, biotechnology, medical technology and healthcare services. The fund is managed with a long-term investment horizon and an active investment strategy focused on a selection of companies, where regional and thematic analyses are also key features of the strategy. The fund complies with Swedbank Robur’s Responsible Investment Policy. Read more about the policy in the fund’s Information Brochure and swedbankrobur.se. Sustainability and climate work is an integrated part in our investment strategy. The fund consists of share classes, for more information see the Information Brochure. The fund is suitable for those who believe in the healthcare industry.

ISIN

SE0014261871

Rtn. this y

3.32 %

Total fee

1.29 %

Risk

4 / 7

Fund type

Equity

Morningstar Rating Total

Morningstar Rating är 3 av 5 stjärnor

SFDR Classification

Article 8

Fact Sheet ​(PRIIPs KID)

Returns

Asset Manager Comment

Updated 2026-07-07

The healthcare sector rose during the month of June. Pharmaceuticals, and particularly early-stage biotechnology companies, performed well, and the American health insurance companies also developed positively. Healthcare and medtech stocks also moved higher as a group, though less strongly.

The gains during the month were driven primarily by the pharmaceutical and biotechnology sectors, which together account for just under two-thirds of the index. The strong rally may have been partly attributable to a slowdown in the technology sector, leading investors to reallocate capital to the pharmaceutical sector. But there were also sector-specific events. In addition, pharmaceutical company AbbVie made a bid for biotechnology firm Apogee to gain access, among other assets, to the drug candidate zampilimab, which is being developed to treat moderate-to-severe eczema and asthma. The acquisition is a strong strategic fit with AbbVie's portfolio and can be regarded as a relatively low-risk transaction. UK-based pharmaceutical company GSK made a bid for oncology company Nuvalent to gain access to a number of niche drug candidates for the treatment of lung cancer. Both bids were well received by the stock market. Together with a number of smaller transactions, these deals marked a continuation of an acquisition-intensive spring and helped boost the emerging biotechnology sector. In addition, German conglomerate Merck launched a bid for life sciences company Bio-Techne, a leading provider of research tools. Merck has a strong track record of successful acquisitions, and the deal may signal improving prospects for suppliers to the pharmaceutical industry, a segment that has experienced a prolonged period of sideways share price performance.

During June, the fund initiated positions in pharmaceutical company Novartis and medical technology companies Stryker and Terumo. It also increased its holdings in pharmaceutical distributor Cardinal Health and health insurer UnitedHealth Group. The fund exited its positions in medical technology company Boston Scientific, pharmaceutical companies Gilead and Roche, and pharmaceutical distributor McKesson.

Pharmaceutical companies Eli Lilly, AbbVie, and Merck were the largest contributors to the fund's performance during the month. The largest negative contributors to the fund's performance were Boston Scientific and pharmaceutical company Gilead.

Management

Markus Wistrand

Managed the fund since

2022-03-07

Markus Wistrand

Markus Wistrand manages Swedbank Robur Healthcare. He has extensive experience from the healthcare sector and joined Swedbank Robur in 2022. 

Experience and education
He has previously worked as Managing Director at HealthInvest Partners (2014-2022), where he also worked as financial analyst (2006-2022). Prior to this, he worked as development coordinator at Q-med (2006).

Markus has an M.Sc in Business Administration from Stockholm School of Economics (2005) and an M.Sc in Biotechnology from Uppsala University (1996-2002). He has also an PhD in Computational Biology from Karolinska Institutet (2002-2006).

Global equities team

Our global equities team invests in the majority of the markets around the world. The fund managers are responsible for their individual funds and select the companies to invest in, at the same time as the entire team works closely together, sharing knowledge and ideas. The team consists of eleven portfolio managers, and they are supported by our sustainability analysts and corporate governance specialists, which gives them a unique and broad basis for their investments.

Active equity funds

The actively managed equity funds apply an investment strategy based on analysis of fundamentals. The focus is on the selection of companies, but sector, regional and thematic analyses are also key components of the strategy. The fund managers strive through active management to attain a return that exceeds the average return in the markets where the funds invest, in other words, a return that exceeds the fund’s benchmark index. Our fund managers integrate sustainability as a natural component of the funds’ investment processes.

Region

United States of America
72.68 %
Sweden
7.64 %
United Kingdom
7.00 %
Switzerland
2.31 %
Belgium
2.16 %
Other
8.21 %

Updated: 30/06/2026

Industry

Health Care

96.44 %

Bank account & Other

3.56 %

Industrials

0.00 %

Information Technology

0.00 %

Other

0.00 %

Updated: 30/06/2026

Largest holdings

Eli Lilly & Co

9.74 %

AbbVie Inc

7.24 %

Merck & Co Inc

7.03 %

AstraZeneca PLC

7.02 %

Thermo Fisher Scientific Inc

5.92 %

Updated: 30/06/2026

Fees

Total fee

1.29 %

Ongoing costs

1.26 %

Of which

Management fee

1.25 %

Transaction costs

0.03 %

Performance based fee

-

Risk

Risk (SRI)

4 / 7

Sharpe ratio 2 y

-0.75 %

Standard Deviation 2 y

14.47 %

Active risk 2 y

1.84 %

Fund Facts

Management Company

Swedbank Robur Fonder AB

Share Class

C

Dividend

No

ISIN

SE0014261871

Base Currency

EUR

Share Class Currency

EUR

Start date

05/02/2021

NAV-price

13.09 EUR

Asset Under Management

14,679.95 MSEK

Type

Equity

Legal seat

Sweden

UCITS

Yes

Benchmark

MSCI World Health Care Net

NAV Update

Daily

PPM-number

-

Morningstar Rating Total

Morningstar Rating är 3 av 5 stjärnor

Sustainability

SFDR Classification

Article 8

CO₂

1/1

Sustainable bonds

-

Exclusion level

Policy

ESG rating

A

Sustainable Finance Disclosures

Summary


This financial product promotes environmental or social characteristics, but does not have a sustainable investment objective. However, the fund will have a minimum share of sustainable investments.

The fund analyses how the sustainable investments affect such things as emissions, water and biodiversity on an ongoing basis. The fund also ensures that the holdings do not seriously and systematically infringe on accepted international standards and conventions relating to sustainability as adopted by the UN, ILO and OECD or are otherwise involved in unacceptable operations relating to sustainability or corporate governance.

External suppliers will provide Swedbank Robur with an analysis of which companies can be associated with violations of international norms. Based on information from our suppliers and other available information, Swedbank Robur will make its own assessment on whether it is a question of a serious and systematic violation. If such a violation is deemed to occur, the company's securities are not a sustainable investment.

The fund promotes low emissions of carbon dioxide, a net zero target, business strategies that include the UN Global Goals (SDGs), an environmentally more sustainable approach by the activities of companies through Environmental Engagement (E) and an increased social responsibility on the part of companies through Social Engagement (S).

Sustainability and climate work constitute an integrated part of the investment strategy in order to manage sustainability and climate risks and to promote environmental and social characteristics. The fund is obligated to follow the Management Company’s "Policy for Responsible Investments" (adopted by the Board) and uses three overarching methods ("include", "exclude" and "engage") in order to achieve the environmental and social characteristics promoted by the fund. The fund follows the Management Company’s "Principles for Shareholder Engagement" (adopted by the Board). As an active owner, the aim of Swedbank Robur is that the companies we invest in are managed in an efficient and long-term sustainable manner.

There are plans for at least 80% of the fund's assets to consist of investments aligned with environmental or social characteristics, of which at least 60% will be sustainable investments.

The Management Company’s risk function monitors and checks that the environmental or social characteristics that the fund promotes are complied with. The risk function also performs a quarterly follow-up and analysis of the metrics the Management Company has selected to measure how the fund’s investments promote environmental or social characteristics.

In order to measure the attainment of the environmental and social characteristics that the fund promotes, the sustainability indicators weighted average carbon dioxide intensity, net zero target, SDG aligned revenues, Environmental Engagement (E) and Social Engagement (S) are used.

Swedbank Robur uses several sources in its process to measure how funds promote environmental and social characteristics. Swedbank Robur purchases data from major data providers that have demonstrated a robust method for guaranteeing the quality of data. In order to guarantee the quality of the data purchased, the supplier's data and product range are reviewed. When there is an opportunity, test data is taken from several providers offering the same product in order to compare as large a selection as possible.

There are a number of limitations with the models and data being currently used. The main limitation is the number of asset allocations for which metric calculation methods exist. The coverage is generally good for the funds, where a mix between reported and estimated data is used. Furthermore, Swedbank Robur believes that the method used by the data provider for estimating data is reliable.

The Management Company has due diligence procedures in place in order to ensure that sustainability risks and the sustainability requirements established for the fund are taken into consideration in the investment decision. Sustainability analysis is an integrated part of the fund management’s investment process. In order to manage sustainability risks and integrate the risks in investment decisions, the fund management follows the procedures that the Management Company describes in the Management Company’s "Strategy to include" and "Strategy to exclude". The Management Company’s risk function performs a daily inspection to determine whether the fund’s holdings fulfil its sustainability requirements and regulations regarding exclusion.

The fund follows the Management Company's "Principles for Shareholder Engagement" (adopted by the Board). In the event of sustainability-related controversies in invested companies, Swedbank Robur has special procedures and processes to monitor and follow up with the company. Both dialogue work and voting are key tools to try to prevent and respond to sustainability-related controversies.

Principal Adverse Impact Statement (in Swedish).